Out of stock

This item is currently unavailable

Gone for 141 days. Could come back at any time — we're watching for you.

Out of stock 141 days · last price £191

Global Pharmaceutical Industry and New Drug Market Trends – Analysis by Company: DATABOOK 2024, Part IV. Company Analysis

Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 343 days · 343 data points (no recent data)

Historical
Generating forecast…
£191.08 £181.53 £185.35 £189.17 £192.99 £196.81 £200.63 23 November 2025 16 February 2026 13 May 2026 06 August 2026 31 October 2026
View at Amazon ↗
Out of stock

Price data last checked 20 day(s) ago - will refresh soon

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 343 days • 1 price levels

Days at Price
343 days 0 86 172 257 343 £191 Days at Price

Price Analysis

Most common price: £191 (343 days, 100.0%)

Price range: £191 - £191

Price levels: 1 different prices over 343 days

Description

We compiled nearly all publicly announced new drug development news in 2024 from the top 30 global pharmaceutical companies, categorizing them into Approvals, Submissions, Other Regulatory (including breakthrough therapy designations and accelerated reviews), Clinical Studies, and Business Development (including licensing deals and collaborations) In this report, the top 30 companies are divided into three groups. The Global Top 10, including Pfizer, Merck, Johnson & Johnson, AbbVie, AstraZeneca, Roche, Novartis, Bristol Myers Squibb, Eli Lilly, and Sanofi, dominate worldwide prescription drug sales with broad, diversified portfolios and extensive global reach. The Global Mid-Tier consists of companies with strong but more specialized or regionally focused portfolios, including Novo Nordisk, GlaxoSmithKline, Amgen, Takeda, Gilead, Bayer, Regeneron, Astellas, Daiichi Sankyo, and Otsuka Holdings. Daiichi Sankyo and Otsuka were included instead of Teva and Boehringer Ingelheim because Teva’s portfolio is primarily generics, and Boehringer Ingelheim is privately held with limited public data, whereas the two Japanese firms provide consistent, proprietary pharmaceutical sales data. Finally, the Biotech & Others group encompasses smaller, innovation-driven companies such as Vertex, Biogen, Chugai, UCB, Eisai, Incyte, Lundbeck, Alnylam, and Boehringer Ingelheim, which often focus on novel therapies, high-growth pipelines, and collaborations with larger pharmaceutical companies. Together, these 30 companies illustrate both the market’s concentration and the diverse strategies of leading, mid-tier, and biotech-focused players. R&D Updates: In 2024, the top 10 pharmaceutical companies led global R&D, achieving 14 initial approvals and 47 additional approvals, alongside 5 grants, 22 filings, and 71 clinical advances. They recorded 11 clinical setbacks and completed 7 business development/licensing (BDL) deals, reflecting strong investment in both regulatory achievements and pipeline growth. The next 10 mid-tier companies achieved 7 initial approvals and 14 additional approvals, with 7 grants, 10 filings, 39 clinical advances, 8 setbacks, and 1 BDL transaction, showing a balanced focus on regulatory milestones and clinical progression. Biotech and other companies, typically smaller or innovation-driven, recorded 7 initial approvals, 3 filings, 7 clinical advances, 5 setbacks, and 1 BDL deal, reflecting targeted yet active R&D pipelines. Collectively, the top 30 companies achieved 28 initial approvals, 61 additional approvals, 15 grants, 39 filings, 135 clinical advances, 24 setbacks, and 9 BDL deals, underscoring robust global R&D activity across both large pharma and biotech innovators. Pipeline: These 30 companies maintain strong Phase 3+ pipelines, comprising 362 drugs across 572 projects, analyzed by therapeutic area and company group. Top 10 companies lead the global pipeline, with 198 oncology drugs, 87 immunology drugs (152 projects), 28 CVMR drugs (64 projects), 22 anti-infectives (34 projects), 18 neurology drugs (20 projects), 14 rare disease drugs (16 projects), 19 in other areas (23 projects), and 10 miscellaneous drugs. Oncology and immunology remain their primary focus. Mid-tier companies have a balanced portfolio: 106 oncology drugs, 38 immunology (74 projects), 9 CVMR (18 projects), 11 anti-infectives (18 projects), 11 neurology (12 projects), 5 rare disease (7 projects), 20 in other areas, and 12 miscellaneous drugs (15 projects), combining scale with moderate diversification. Biotech & Other companies focus on innovation and specialization: 58 oncology, 11 immunology (21 projects), 8 CVMR (12 projects), 7 anti-infectives (10 projects), 0 neurology, 19 rare disease (23 projects), 9 other areas (12 projects), and 4 miscellaneous drugs (7 projects).

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
14 November 2025
Listed Since
21 November 2025

Barcode

No barcode data available

Similar Products You Might Like

Overview of the Pharmaceutical Industry and New Drug Market Trends: Perspectives and Insights: DATABOOK 2024, Part I. Strategic Overview of the Global Pharmaceutical Industry
99% match

Overview of the Pharmaceutical Industry and New Drug Market Trends: Perspectives and Insights: DATABOOK 2024, Part I. Strategic Overview of the Global Pharmaceutical Industry

Price unavailable
Global Pharmaceutical Industry and New Drug Market Trends – Analysis by Pharmacology Classes: DATABOOK 2024, Part III. Pharmacology Classes
99% match

Global Pharmaceutical Industry and New Drug Market Trends – Analysis by Pharmacology Classes: DATABOOK 2024, Part III. Pharmacology Classes

Price unavailable
グローバル製薬産業の現状と新薬市場の動向治療分野編: ファーマセット・リサーチ DATABOOK 2024
98% match

グローバル製薬産業の現状と新薬市場の動向治療分野編: ファーマセット・リサーチ DATABOOK 2024

Price unavailable
グローバル製薬産業の現状と新薬市場の動向薬効クラス編: ファーマセット・リサーチ DATABOOK 2024
98% match

グローバル製薬産業の現状と新薬市場の動向薬効クラス編: ファーマセット・リサーチ DATABOOK 2024

Price unavailable
グローバル製薬産業の現状と新薬市場の動向企業編: ファーマセット・リサーチ DATABOOK 2024
98% match

グローバル製薬産業の現状と新薬市場の動向企業編: ファーマセット・リサーチ DATABOOK 2024

Price unavailable
Global Pharmaceutical Industry and New Drug Market Trends Databook
98% match

Global Pharmaceutical Industry and New Drug Market Trends Databook

Price unavailable
The Futurist Investor's Guide to Tomorrow's Opportunities: Volume 2: Disruptive Trends, Fintech, Advanced Materials, and Smart Mobility (SYL+JAS Bureau Series in The World of Investing and Crypto)
98% match

The Futurist Investor's Guide to Tomorrow's Opportunities: Volume 2: Disruptive Trends, Fintech, Advanced Materials, and Smart Mobility (SYL+JAS Bureau Series in The World of Investing and Crypto)

£78.71 13 Oct 2026
Practitioner Database (Book Two): A Holistic Approach to Detoxing & Immune Issues (Practitioner Database Collection)
98% match

Practitioner Database (Book Two): A Holistic Approach to Detoxing & Immune Issues (Practitioner Database Collection)

£73.13 26 Sep 2026
Artificial Intelligence (AI) and Patient Empowerment: 3 (Health IT & AI Instruction Series)
98% match

Artificial Intelligence (AI) and Patient Empowerment: 3 (Health IT & AI Instruction Series)

Price unavailable
Digital Pharma Flow: The 2026 Playbook (Center of Excellence - Pharma 4.0)
98% match

Digital Pharma Flow: The 2026 Playbook (Center of Excellence - Pharma 4.0)

£79.99 30 Sep 2026
PV: PHARMACOVIGILANCE: Safety Aspects for Medical Devices
98% match

PV: PHARMACOVIGILANCE: Safety Aspects for Medical Devices

£181.75 17 Nov 2026
The Digital Pillbox: Integrating AI, IoT, and Pharma Solutions (Part 1)
98% match

The Digital Pillbox: Integrating AI, IoT, and Pharma Solutions (Part 1)

£78.90 17 Sep 2026
ADVANCE PRINCIPLES OF ARTIFICIAL INTELLIGENCE IN MEDICINE: A Comprehensive Guide to Clinical Applications, Machine Learning, and Healthcare Innovation
98% match

ADVANCE PRINCIPLES OF ARTIFICIAL INTELLIGENCE IN MEDICINE: A Comprehensive Guide to Clinical Applications, Machine Learning, and Healthcare Innovation

Price unavailable
The Digital Pillbox: Integrating AI, IoT, and Pharma Solutions (Part 2)
98% match

The Digital Pillbox: Integrating AI, IoT, and Pharma Solutions (Part 2)

£78.91 26 Sep 2026
The Digital Pillbox: Integrating AI, IoT, and Pharma Solutions (Part 2)
98% match

The Digital Pillbox: Integrating AI, IoT, and Pharma Solutions (Part 2)

£78.91 17 Sep 2026
The Digital Pillbox: Integrating AI, IoT, and Pharma Solutions (Part 1)
98% match

The Digital Pillbox: Integrating AI, IoT, and Pharma Solutions (Part 1)

£78.91 13 Sep 2026
Data Center Operations Training Mastery Course: Book 4 (Engineering Fully Automated Data Centers)
98% match

Data Center Operations Training Mastery Course: Book 4 (Engineering Fully Automated Data Centers)

£59.68 23 Sep 2026
PHYTOGRAPHIE MÉDICALE Tome 4: HISTOIRE DES SUBSTANCES HÉROÏQUES ET DES POISONS
98% match

PHYTOGRAPHIE MÉDICALE Tome 4: HISTOIRE DES SUBSTANCES HÉROÏQUES ET DES POISONS

£67.08 23 Sep 2026
ANÁLISIS DE LA FORMACIÓN DEL PROFESORADO EN PLATAFORMAS A TRAVÉS DEL MODELO TicPK
98% match

ANÁLISIS DE LA FORMACIÓN DEL PROFESORADO EN PLATAFORMAS A TRAVÉS DEL MODELO TicPK

£71.11 18 Sep 2026
Master Your Life In 30 Days: A Routine Blueprint
98% match

Master Your Life In 30 Days: A Routine Blueprint

£8.98 31 Oct 2026
AI - Driven - Closed-Loop Control: A Recipe for Factory of the Future
98% match

AI - Driven - Closed-Loop Control: A Recipe for Factory of the Future

£115.09 01 Oct 2026
Business Analytics in the Age of AI: A New Paradigm for Executives
98% match

Business Analytics in the Age of AI: A New Paradigm for Executives

£73.40 12 Sep 2026
PharmaNext: Shaping Tomorrow’s Healthcare from India’s Innovation Engine
98% match

PharmaNext: Shaping Tomorrow’s Healthcare from India’s Innovation Engine

£67.76 08 Mar 2026
98% match

Optics and Photonics in Global Homeland Security IV: 4 (Proceedings of SPIE)

£115.00 30 Sep 2026